Skip to main content
. 2020 Jun 26;12(6):e8845. doi: 10.7759/cureus.8845

Table 5. Characteristics of clinical trials studying baricitinib in patients with COVID-19.

Clinical trial ID Status Study Results Conditions Interventions Locations
NCT04321993 Recruiting No results available COVID-19 Drug: Lopinavir/ritonavir drug: Hydroxychloroquine sulfate drug: Baricitinib Canada
NCT04401579 Recruiting No results available COVID-19 Other: Placebo drug: Remdesivir drug: Baricitinib USA